New Horizons in Migraine Therapy: Efficacy and Mechanisms of CGRP Inhibitors

Contents

1. Introduction
2. Discovery of CGRP and Its Role in Migraine
3. Development of CGRP Inhibitors
4. Mechanism of Action of CGRP Inhibitors
5. Current CGRP Inhibitors Available
6. Comparative Efficacy and Safety of CGRP Inhibitors
7. Advantages of Newer CGRP Inhibitors
8. Access and Availability: Navigating the Landscape of CGRP Inhibitors
9. Future Directions in CGRP Inhibitor Research and Clinical Application
10. Conclusion: Shaping the Future of Migraine Treatment with CGRP Inhibitors

1. Introduction

Migraine remains one of the most prevalent and debilitating neurological disorders worldwide, affecting approximately one billion individuals globally. Characterized by recurrent episodes of severe headache, often accompanied by nausea, photophobia, and phonophobia, migraine imposes a substantial burden not only on affected individuals but also on healthcare systems. Traditional pharmacological treatments have focused predominantly on symptomatic relief during acute attacks and the use of non-specific prophylactic medications, which are often limited by partial efficacy and considerable side effects.

The advent of calcitonin gene-related peptide (CGRP) inhibitors has ushered in a transformative era in migraine prophylaxis. CGRP, a neuropeptide highly abundant in the trigeminovascular system, has been identified as a critical mediator in the pathophysiology of migraine, involved in both vasodilation and the transmission of pain. The discovery that CGRP levels are elevated during migraine attacks provided a novel therapeutic target, leading to the development of specific inhibitors that could prevent migraine by intervening directly in its pathogenic mechanisms.

This new class of medication includes both monoclonal antibodies that target the peptide or its receptor and small molecule gepants that block the receptor, offering a prophylactic approach tailored to disrupt CGRP’s pathogenic actions. Since the approval of the first CGRP inhibitor in 2018, these drugs have demonstrated significant efficacy in reducing migraine frequency, severity, and associated disability, fundamentally altering the landscape of migraine management.

2. Discovery of CGRP and Its Role in Migraine

The journey towards understanding the role of calcitonin gene-related peptide (CGRP) in migraine began with pivotal research that elucidated the neuropeptide’s widespread distribution and multifunctional role in the central and peripheral nervous systems. CGRP is primarily synthesized by both central and peripheral neurons and is one of the most potent vasodilators known in the cerebral circulation system.

In the late 1980s, pioneering studies identified elevated levels of CGRP in the external jugular vein during migraine attacks, suggesting its involvement in the pathophysiology of migraine. Subsequent research confirmed that CGRP could trigger migraine-like headaches in individuals susceptible to migraines, indicating a causative role rather than a mere association.

Molecular Mechanisms of CGRP in Migraine

CGRP mediates its effects through the CGRP receptor, which is composed of a G-protein coupled receptor called the calcitonin receptor-like receptor (CLR), coupled with a single transmembrane protein called receptor activity-modifying protein 1 (RAMP1). This receptor complex is abundantly expressed in regions of the nervous system involved in migraine pathology, including the trigeminal ganglion and dorsal root ganglia.

During a migraine attack, trigeminal nerve activation results in the release of CGRP, leading to vasodilation of cranial blood vessels and modulation of pain pathways. The elevated concentration of CGRP enhances nociceptive signaling within the central nervous system, contributing to the pain and other symptoms associated with migraine.

CGRP as a Therapeutic Target

The clear linkage between CGRP release and migraine symptoms provided a compelling target for therapeutic intervention. The development of CGRP inhibitors was based on the premise that blocking this peptide or its receptor could prevent the onset of migraine attacks. This hypothesis was confirmed through clinical trials that demonstrated the efficacy of CGRP antagonists in reducing the frequency and severity of migraine attacks, marking a significant advancement in migraine prophylaxis.

3. Development of CGRP Inhibitors

The development of CGRP (calcitonin gene-related peptide) inhibitors represents a convergence of decades of research into the pathophysiology of migraines and the sophisticated biotechnological application of this knowledge. The journey to these inhibitors began with foundational studies in the late 20th century that identified CGRP as a key neuropeptide involved in migraine pathology, primarily due to its potent vasodilatory effects on cerebral blood vessels and its role in pain signaling pathways.

Initial Research and Conceptualization

Research into CGRP began in earnest when it was discovered that levels of this peptide were significantly elevated in patients during migraine episodes. Early studies utilizing radioimmunoassay techniques documented elevated CGRP levels in the jugular blood during migraine attacks, prompting further investigation into its role in headache pathology. This correlation between CGRP and migraine episodes was pivotal, establishing CGRP as a promising therapeutic target.

Biochemical Characterization of CGRP

CGRP is a 37-amino acid peptide resulting from the alternative splicing of the calcitonin gene. It exists in two forms, α-CGRP and β-CGRP, with α-CGRP being predominantly involved in neurological pathways. CGRP exerts its effects through the CGRP receptor, which is a complex of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). This receptor is primarily expressed in sensory neurons of the trigeminal ganglion and vascular smooth muscle cells, which are central to migraine’s pathophysiological mechanisms.

Development of CGRP Receptor Antagonists and Antibodies

The realization that CGRP could be a therapeutic target led to the development of two main classes of CGRP inhibitors: receptor antagonists and monoclonal antibodies. The receptor antagonists, or “gepants,” were among the first to be developed. These small molecules inhibit CGRP receptor function by competitively binding to the receptor, preventing CGRP from eliciting its physiological effects. Gepants such as olcegepant and telcagepant paved the way for further development, although some, like telcagepant, were discontinued due to liver toxicity issues.

Parallel to the development of gepants, significant advances were made in the field of monoclonal antibodies. These antibodies are designed to target either the CGRP molecule itself or its receptor. The development of monoclonal antibodies such as erenumab, fremanezumab, and galcanezumab involved detailed mapping of the CGRP and its receptor interactions, followed by the creation of antibodies that could effectively neutralize the action of CGRP or block its binding to the receptor. Erenumab, for instance, specifically binds to the CGRP receptor and is used for the preventive treatment of migraine, representing a novel approach by targeting the receptor rather than the peptide itself.

Clinical Trials and Regulatory Milestones

The translation of these biochemical and pharmacological insights into clinical applications involved extensive clinical trials that demonstrated the efficacy and safety of these novel inhibitors. These studies were critical in elucidating the dosage, administration routes, and potential side effects of CGRP inhibitors. The success of these trials led to the approval of the first of these drugs by regulatory bodies such as the FDA, marking a new era in migraine prophylaxis.

The development of CGRP inhibitors is a prime example of how targeted molecular therapy can revolutionize treatment paradigms in neurology, specifically for chronic conditions such as migraine. By blocking the effects of CGRP, these drugs offer new hope for millions of patients suffering from this debilitating condition, significantly reducing migraine frequency and intensity.

4. Mechanism of Action of CGRP Inhibitors

The efficacy of CGRP inhibitors in migraine prevention is fundamentally due to their specific interactions with the CGRP pathway, which plays a crucial role in the modulation of migraine pain and vasodilation associated with migraine attacks. Understanding the mechanism of action of these inhibitors requires a deep dive into the molecular biology of the CGRP receptor and its ligand, CGRP itself.

CGRP and its Receptor Complex

CGRP functions by binding to a complex receptor system consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). This receptor complex is primarily expressed in the trigeminal ganglion, which is key in the pathophysiology of migraine. Upon binding of CGRP to its receptor, a cascade of intracellular signaling is initiated, leading to the activation of adenylate cyclase and increased production of cyclic AMP (cAMP). The rise in cAMP levels ultimately results in vasodilation and transmission of pain signals that are characteristic of migraine episodes.

Monoclonal Antibodies Targeting CGRP or its Receptor

The monoclonal antibodies developed to combat migraines target this pathway in two distinct ways:

1. Antibodies Targeting CGRP:
   Fremanezumab and galcanezumab are examples of monoclonal antibodies that bind directly to the CGRP peptide, preventing it from interacting with its receptor. By neutralizing the peptide, these antibodies inhibit the downstream signaling that leads to migraine symptoms.
   
2. Antibodies Targeting the CGRP Receptor:
   Erenumab is unique among the CGRP inhibitors as it binds directly to the CGRP receptor (CLR-RAMP1 complex). This prevents the natural ligand, CGRP, from binding to its receptor, thereby blocking the subsequent pain transmission and vasodilatory signaling pathway.

Small Molecule CGRP Receptor Antagonists (Gepants)

Gepants, such as rimegepant and ubrogepant, operate through a slightly different mechanism. These small molecules bind competitively to the CGRP receptor, obstructing CGRP’s natural interaction with its receptor without causing receptor activation. Their ability to cross the blood-brain barrier due to their small size makes them effective not only for preventive treatment but also for the acute management of migraines.

Mechanism Benefits and Pharmacological Effects

The blocking of CGRP receptors or neutralization of CGRP itself decreases the overall activity within the trigeminovascular system, which is hypersensitive in individuals suffering from migraines. This reduction in activity lessens both the frequency and intensity of migraine episodes. Furthermore, these inhibitors offer a significant benefit in terms of safety and tolerability, as they do not cause vasoconstriction — a common side effect associated with some other migraine treatments.

These detailed interactions between CGRP inhibitors and the migraine pathophysiology illustrate a profound shift in migraine management, moving from symptomatic treatment to directly modifying the disease pathway at the molecular level.

5. Current CGRP Inhibitors Available

The landscape of CGRP inhibitors has evolved rapidly since the introduction of the first drug in this class. Currently, several CGRP inhibitors are approved for clinical use, each with distinct properties concerning administration methods, dosing schedules, and regulatory approvals. Here, we provide a detailed overview of each available CGRP inhibitor.

Erenumab (Aimovig)

• Mechanism: Erenumab is a fully human monoclonal antibody that blocks the CGRP receptor.
• Administration: Subcutaneous injection.
• Dosing Schedule: Typically administered once monthly with a dose of 70 mg or 140 mg.
• Regulatory Approval: Approved by the FDA in May 2018, Erenumab was the first CGRP inhibitor to receive approval for the preventive treatment of migraine in adults.

Fremanezumab (Ajovy)

• Mechanism: Fremanezumab is a humanized monoclonal antibody that binds to the CGRP ligand, preventing it from activating the receptor.
• Administration: Subcutaneous injection.
• Dosing Schedule: Available in two dosing options, either once monthly (225 mg) or quarterly (675 mg).
• Regulatory Approval: FDA approved in September 2018, Fremanezumab offers flexibility in dosing frequency to accommodate patient preferences and treatment needs.

Galcanezumab (Emgality)

• Mechanism: Similar to Fremanezumab, Galcanezumab is a human monoclonal antibody that binds to CGRP, inhibiting its biological activity.
• Administration: Subcutaneous injection.
• Dosing Schedule: Administered monthly at a dose of 120 mg, following an initial loading dose of 240 mg.
• Regulatory Approval: Galcanezumab received FDA approval in September 2018 and is indicated for the prevention of migraine in adults.

Eptinezumab (Vyepti)

• Mechanism: Eptinezumab is a humanized monoclonal antibody that targets the CGRP ligand.
• Administration: Intravenous infusion.
• Dosing Schedule: Administered every three months, typically at a dose of 100 mg or 300 mg.
• Regulatory Approval: Approved by the FDA in February 2020, Eptinezumab is unique in its intravenous administration route, catering to patients looking for less frequent dosing intervals.

These CGRP inhibitors represent a significant advancement in migraine management, providing targeted, effective preventive treatment options with favorable safety profiles. Their development and approval have not only expanded the therapeutic arsenal against migraines but have also underscored the importance of personalized medicine in chronic disease management.

6. Comparative Efficacy and Safety of CGRP Inhibitors

As the range of CGRP inhibitors has expanded, so too has the body of research assessing their efficacy and safety. These drugs have been pivotal in transforming migraine management, with clinical trials consistently demonstrating significant reductions in migraine frequency, severity, and the need for acute medication. This section compares the efficacy and safety profiles of the available CGRP inhibitors, emphasizing their impact on patient quality of life.

Efficacy Across Different CGRP Inhibitors

• Erenumab (Aimovig): Clinical trials have shown that Erenumab effectively reduces monthly migraine days by approximately 50% for many patients, particularly those with chronic migraine.
  
• Fremanezumab (Ajovy): Studies have reported that both monthly and quarterly dosing significantly decreases the number of migraine days compared to placebo, with similar efficacy between dosing intervals.
  
• Galcanezumab (Emgality): Trials indicate that Galcanezumab reduces monthly migraine days with sustained efficacy over a six-month period. It is particularly effective in those who have previously not responded to other preventive medications.
  
• Eptinezumab (Vyepti): Demonstrating rapid onset, Eptinezumab has been shown to reduce migraine frequency starting from day 1 post-infusion, with continued effectiveness over quarterly administration periods.

Safety and Tolerability

CGRP inhibitors are generally well tolerated, with a low incidence of serious adverse effects. The most common side effects reported across all CGRP inhibitors include injection-site reactions and constipation, but these are typically mild and manageable. Notably, unlike many traditional migraine treatments, CGRP inhibitors do not cause vasoconstriction, making them a safer option for patients with cardiovascular risk factors.

• Injection-site reactions: More common in subcutaneously administered drugs (Erenumab, Fremanezumab, Galcanezumab).
  
• Constipation and nausea: These side effects are occasionally reported but usually do not lead to discontinuation of therapy.
  
• Antibody development: Long-term use has led to the development of antibodies in a small percentage of patients, though this rarely impacts the efficacy of the treatment.

Impact on Patient Quality of Life

The introduction of CGRP inhibitors has marked a substantial improvement in quality of life for many patients. This is attributed to their high efficacy, reduced side effect profile, and dosing convenience which significantly decrease the burden of disease. Studies report improvements in physical functioning, reduced disability, and lower impact of migraine on day-to-day activities.

• Work productivity: Patients receiving CGRP inhibitors often experience fewer workdays lost to migraines, contributing to better overall productivity.
  
• Mental health: Reductions in migraine frequency and severity are associated with improvements in anxiety, depression, and overall mental health.

Comparative Studies

Comparative studies of CGRP inhibitors generally show no significant differences in efficacy between the drugs, which suggests that the choice of drug can be tailored based on patient preferences for administration route and dosing frequency, as well as individual tolerance and response.

The development of CGRP inhibitors represents a significant breakthrough in migraine prophylaxis, offering patients effective and safer long-term treatment options. This comparative analysis underlines the importance of individualized treatment plans and continuous monitoring of therapeutic outcomes to optimize patient care.

7. Advantages of Newer CGRP Inhibitors

The introduction of CGRP inhibitors has redefined the therapeutic landscape for migraine, shifting the focus from broad-spectrum pharmacological treatments to targeted molecular interventions. This transition is not just a testament to the advances in migraine pathophysiology understanding but also highlights a broader movement towards precision medicine in neurology.

A Targeted Approach to Migraine Prophylaxis

CGRP inhibitors have carved a niche in migraine management through their specificity. Traditional migraine treatments often employed a one-size-fits-all approach, utilizing medications like beta-blockers, anticonvulsants, and calcium channel blockers, which were initially developed for other diseases and repurposed for migraine. While effective for some, these treatments could induce a range of unwanted side effects due to their broad mechanism of action.

In contrast, CGRP inhibitors directly target the calcitonin gene-related peptide, a key mediator in migraine pathogenesis known to facilitate the transmission of pain and induce inflammation and vasodilation during migraine attacks. By specifically blocking this peptide or its receptor, CGRP inhibitors minimize the typical side effects associated with older therapies, offering a cleaner profile for long-term use.

Enhancing Patient Compliance and Quality of Life

The benefits of CGRP inhibitors extend beyond their pharmacological action. The dosing regimen of these drugs—whether through monthly injections or quarterly infusions—provides a level of convenience and efficacy that significantly enhances patient compliance. The ability to maintain consistent therapeutic levels of the medication without daily dosing reduces the ‘treatment burden’ often experienced by patients, which can be a significant barrier to adherence.

Moreover, the impact of CGRP inhibitors on patients’ quality of life is profound. By reducing the frequency and severity of migraine attacks, these medications allow individuals to reclaim their daily activities, reduce their overall healthcare utilization, and minimize the psychological burden associated with chronic migraine. This improvement in quality of life is a key driver in patient satisfaction and is crucial for long-term treatment success.

Economic Benefits and Healthcare Efficiency

The precise action of CGRP inhibitors also translates into direct and indirect economic benefits. By effectively reducing migraine episodes, these treatments decrease the need for acute migraine medications and reduce emergency healthcare services usage. The reduction in migraine-related healthcare visits not only alleviates the strain on healthcare systems but also contributes to a decrease in overall healthcare costs associated with migraine management.

Conclusion

As we continue to embrace these advanced therapies, the advantages of CGRP inhibitors are becoming increasingly apparent, not only in clinical outcomes but also in enhancing patient quality of life and reducing the economic burden of migraines. This paradigm shift in migraine prophylaxis reflects a broader trend in healthcare towards more targeted, effective, and patient-friendly treatments. The future of migraine management, bolstered by ongoing research and innovation, promises even greater advancements, potentially offering hope to those who have struggled with conventional therapies.

8. Access and Availability: Navigating the Landscape of CGRP Inhibitors

Despite the clear clinical benefits of CGRP inhibitors, their widespread adoption faces challenges linked to access and availability. These hurdles stem from a complex interplay of regulatory, economic, and logistical factors that can influence a patient’s ability to obtain these advanced treatments.

Regulatory and Approval Challenges Across Regions

The global landscape for CGRP inhibitor availability varies considerably due to differing regulatory frameworks. In the United States, the FDA’s approval of CGRP inhibitors was a landmark event, supported by robust clinical trial data demonstrating their efficacy and safety. However, the journey from approval to patient access is often complicated by insurance requirements, such as mandatory prior authorization and proof of failure with other preventive treatments. These stipulations, while intended to manage costs, can delay treatment initiation for many patients.

In Europe, the EMA has also approved these medications, but each member state’s health authority may impose its own restrictions based on cost-effectiveness assessments and budgetary constraints. For example, the NHS in the UK may limit prescriptions to patients who have chronic migraine and have not responded to other treatments, reflecting a cautious approach to new medication adoption.

Economic Barriers and Insurance Coverage

CGRP inhibitors are high-cost medications, primarily due to their novel mechanism of action and biotechnological production processes. This cost is often passed on to patients through high co-pays or deductibles, especially in systems with significant private health insurance involvement. Insurance companies may also limit the number of doses covered per month, which can affect adherence and overall treatment efficacy.

For many patients, these economic barriers are mitigated through manufacturer-sponsored patient assistance programs, which can provide the medication at a reduced cost or even for free based on financial need. These programs are essential for maintaining access but highlight the broader issue of drug pricing and healthcare equity.

Expanding Global Access through Advocacy and Policy

Addressing the access challenges of CGRP inhibitors requires concerted efforts from multiple stakeholders. Patient advocacy groups play a critical role in this context, lobbying for broader insurance coverage and educating policymakers about the benefits of these treatments. There is also a growing push for regulatory bodies to streamline their approval processes to reduce delays between drug approval and market availability.

Moreover, the introduction of biosimilars and generics in the coming years could significantly reduce costs and improve access. As patents on original CGRP inhibitors expire, the market entry of lower-cost alternatives will likely prompt more competitive pricing and broader usage.

Conclusion

The promise of CGRP inhibitors as a transformative therapy for migraine is indisputable, but realizing their full potential requires overcoming significant access and availability hurdles. By aligning regulatory approaches, expanding insurance coverage, and supporting policy changes that facilitate easier access to these medications, healthcare systems worldwide can ensure that all patients who stand to benefit from CGRP inhibitors can do so. The path forward involves not only scientific innovation but also a commitment to health policy reform and patient advocacy.

9. Future Directions in CGRP Inhibitor Research and Clinical Application

The trajectory of CGRP inhibitors is poised at a promising juncture, with continuous advancements in research and development expected to broaden their impact on migraine treatment. This evolution not only anticipates enhancements in drug efficacy and administration but also a deeper integration into personalized medicine frameworks.

Advancing Pharmacological Efficacy and Drug Delivery

Innovations in the formulation of CGRP inhibitors are aimed at extending the duration of action and improving the bioavailability of these medications. Research into extended-release formulations could decrease the frequency of dosing, thereby improving patient compliance and overall treatment satisfaction. Furthermore, alternative delivery methods such as nasal sprays or transdermal patches are under investigation, which could offer faster onset of action and greater convenience compared to subcutaneous injections or intravenous infusions.

Broader Indications and Expanded Clinical Use

Current research extends beyond the prevention of migraines into other headache disorders where CGRP plays a significant role, such as cluster headaches and tension-type headaches. Preliminary studies suggest that CGRP inhibitors may also be beneficial in these conditions, potentially expanding their therapeutic reach.

Additionally, there is significant interest in the pediatric population, where migraines often go underdiagnosed and undertreated. Tailoring dosages and formulations for children and adolescents could fill this gap and provide early intervention strategies that prevent the progression of migraine severity over time.

Integration of Precision Medicine

The future of CGRP inhibitors lies in the realm of precision medicine, where treatments are customized based on individual genetic profiles and biomarkers. Identifying genetic markers that predict response to CGRP inhibitors can optimize patient selection and improve outcomes. Moreover, ongoing studies are exploring the relationship between CGRP levels and migraine attack severity, which could lead to dynamic dosing strategies where doses are adjusted based on real-time measurements of CGRP levels.

Collaboration and Regulatory Innovations

To facilitate these advancements, collaborative efforts between academic institutions, industry, and regulatory bodies are crucial. These partnerships can accelerate the pace of clinical trials, streamline the regulatory approval process, and ensure that safety profiles are continuously monitored.

The development of international treatment guidelines based on the latest evidence can help standardize care and ensure that patients worldwide receive the most effective and advanced treatments available. Additionally, as patents begin to expire, the introduction of generic versions of CGRP inhibitors will likely promote competitive pricing and more widespread use.

Conclusion

As we look to the future, the landscape of migraine management with CGRP inhibitors is one of immense potential and exciting possibilities. The ongoing commitment to research and development, coupled with strategic collaborations and regulatory support, promises to not only enhance the effectiveness of these therapies but also to revolutionize the way migraines are treated across different patient demographics and geographies. The promise of more personalized, accessible, and effective migraine care is on the horizon, setting a new standard in headache medicine.

10. Conclusion: Shaping the Future of Migraine Treatment with CGRP Inhibitors

As we reflect on the journey of CGRP inhibitors from novel scientific insights to cornerstone migraine treatments, it’s evident that these therapies have not only reshaped our approach to migraine management but have also paved the way for a future where precision medicine becomes the norm in neurology.

The introduction of CGRP inhibitors marked a paradigm shift in our understanding and treatment of migraine, a shift from symptomatic treatment to preventive care that targets the root causes of migraine at the molecular level. The impact of these treatments extends beyond the clinical, influencing every facet of patient life by reducing the frequency and severity of migraine attacks, thereby enhancing daily functioning and overall well-being.

Looking ahead, the potential of CGRP inhibitors is expansive. The ongoing research into their mechanisms and applications promises to broaden their use to other neurological disorders, potentially offering relief to millions more suffering from various types of chronic pain. Furthermore, the advent of longer-acting formulations and non-invasive delivery systems is anticipated to improve patient adherence and satisfaction, making these powerful medications not only more effective but also easier to use.

In the landscape of migraine treatment, CGRP inhibitors are more than just drugs; they are a beacon of hope for millions and a testament to the power of targeted therapy. As we continue to unravel the complexities of migraine and other similar disorders, these inhibitors will undoubtedly play a pivotal role in crafting treatments that are not only effective but also deeply attuned to the needs of each patient.

This moment in medical history is not just about managing symptoms but about transforming lives. The future of migraine treatment with CGRP inhibitors is not just promising; it is bright, filled with the potential for even greater discoveries and innovations that will continue to revolutionize care for migraine sufferers around the world.

Author: David Halenta, April 14, 2024

Note: Before relying on the information in this article, please ensure you have read our Disclaimer for important legal and health information.

Used Sources for the Article:

Clinical Trials and Research Studies: Sources include various clinical trial data and research studies that have documented the efficacy and safety of CGRP inhibitors. These studies provide a foundational understanding of the mechanisms and benefits of these treatments in migraine management.

FDA and EMA Approval Documents: Regulatory documents from the Food and Drug Administration (USA) and the European Medicines Agency provide details on the approval process, indications, and usage guidelines for different CGRP inhibitors.

Healthcare and Medical Journals: Articles and reviews from reputable medical journals that discuss the development, application, and impacts of CGRP inhibitors in the field of neurology and migraine treatment.

Patient Advocacy and Healthcare Policy Reports: Reports from patient advocacy groups and health policy organizations that address issues related to the accessibility and regulatory landscape for CGRP inhibitors.

Economic Impact Studies: Studies that analyze the economic impact of migraine and the potential cost-effectiveness of CGRP inhibitors in reducing the healthcare burden associated with migraine.